Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors
L López, LG Morosi, F La Terza, P Bourdely… - Nature …, 2024 - nature.com
Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T
cell responses to model antigens, in various tumor settings. However, the impact of cross …
cell responses to model antigens, in various tumor settings. However, the impact of cross …
Cancer vaccines: from an immunology perspective
S Makker, C Galley, CL Bennett - Immunotherapy Advances, 2024 - academic.oup.com
The concept of a therapeutic cancer vaccine to activate anti-tumour immunity pre-dates
innovations in checkpoint blockade immunotherapies. However, vaccination strategies have …
innovations in checkpoint blockade immunotherapies. However, vaccination strategies have …
Emerging cytokine delivery with nanomedicine for brain cancer treatment
F Sousa - Expert Opinion on Drug Delivery, 2024 - Taylor & Francis
In recent years, immunotherapy has emerged as a groundbreaking avenue in cancer
treatment. The landscape of immunotherapeutic approaches encompasses immune …
treatment. The landscape of immunotherapeutic approaches encompasses immune …
Toll 样受体激动剂作为佐剂在恶性肿瘤治疗性疫苗中的应用研究进展
牟漫， 黄思剑， 李健伦， 操媛， 王丽娟… - 华中科技大学学报 …, 2024 - tjqk.magtech.com.cn
摘要: 恶性肿瘤严重威胁人类健康和生命, 急需研发新型治疗药物. 治疗性肿瘤疫苗通过刺激患者
免疫系统产生针对特定肿瘤抗原的T 细胞应答, 达到肿瘤治疗的目的, 成为未来肿瘤免疫治疗最 …
免疫系统产生针对特定肿瘤抗原的T 细胞应答, 达到肿瘤治疗的目的, 成为未来肿瘤免疫治疗最 …
Cancer vaccines: from an immunology perspective
S Makker, C Galley, CL Bennett - 2023 - europepmc.org
The concept of a therapeutic cancer vaccine to activate anti-tumour immunity pre-dates
innovations in checkpoint blockade immunotherapies. However, vaccination strategies have …
innovations in checkpoint blockade immunotherapies. However, vaccination strategies have …